TipRanks
Advertisement
Advertisement
Stifel’s Thomas Shrader Reiterates Buy on AC Immune, Citing Diversified Neuroscience Pipeline, Promising NLRP3 Data, and Strong Cash Runway
PremiumRatingsStifel’s Thomas Shrader Reiterates Buy on AC Immune, Citing Diversified Neuroscience Pipeline, Promising NLRP3 Data, and Strong Cash Runway
2M ago
AC Immune posts positive first‑in‑human data for NLRP3 inhibitor ACI‑19764
Premium
Company Announcements
AC Immune posts positive first‑in‑human data for NLRP3 inhibitor ACI‑19764
2M ago
AC Immune receives fast track designation, clearance for ACI-7104 IND
Premium
The Fly
AC Immune receives fast track designation, clearance for ACI-7104 IND
2M ago
AC Immune announces interim data from first three cohorts of ABATE trial
PremiumThe FlyAC Immune announces interim data from first three cohorts of ABATE trial
4M ago
AC Immune Shareholders Back Capital Band, Governance Slate and Pay Caps at June 11 AGM
Premium
Company Announcements
AC Immune Shareholders Back Capital Band, Governance Slate and Pay Caps at June 11 AGM
4M ago
AC Immune Secures $4 Million Goradia Foundation Grant to Extend Phase 2 Parkinson’s Trial
Premium
Company Announcements
AC Immune Secures $4 Million Goradia Foundation Grant to Extend Phase 2 Parkinson’s Trial
4M ago
AC Immune Triggers $12 Million Takeda Milestone as Final ABATE Cohort Starts in Alzheimer’s Trial
PremiumCompany AnnouncementsAC Immune Triggers $12 Million Takeda Milestone as Final ABATE Cohort Starts in Alzheimer’s Trial
6M ago
AC Immune Posts Q1 2026 Update, Extends Cash Runway and Advances Neurodegeneration Pipeline
Premium
Company Announcements
AC Immune Posts Q1 2026 Update, Extends Cash Runway and Advances Neurodegeneration Pipeline
6M ago
Is ACIU a Buy, Before Earnings?
Premium
Pre-Earnings
Is ACIU a Buy, Before Earnings?
6M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―